2016 Q1 Form 10-K Financial Statement
#000114420416086916 Filed on March 09, 2016
Income Statement
| Concept | 2016 Q1 | 2015 Q4 | 2015 Q1 |
|---|---|---|---|
| Revenue | $1.810M | $1.761M | $723.1K |
| YoY Change | 150.35% | 101.56% | -31.92% |
| Cost Of Revenue | $819.5K | $800.0K | $304.5K |
| YoY Change | 169.15% | 142.42% | -54.04% |
| Gross Profit | $990.7K | $957.2K | $418.6K |
| YoY Change | 136.67% | 75.84% | 4.74% |
| Gross Profit Margin | 54.73% | 54.35% | 57.89% |
| Selling, General & Admin | $1.970M | $2.370M | $1.515M |
| YoY Change | 30.03% | -4.44% | 40.23% |
| % of Gross Profit | 198.86% | 247.6% | 361.97% |
| Research & Development | $856.1K | $1.250M | $951.0K |
| YoY Change | -9.98% | 28.87% | 301.66% |
| % of Gross Profit | 86.42% | 130.59% | 227.2% |
| Depreciation & Amortization | $30.00K | $30.00K | $20.00K |
| YoY Change | 50.0% | 0.0% | |
| % of Gross Profit | 3.03% | 3.13% | 4.78% |
| Operating Expenses | $3.081M | $3.620M | $2.682M |
| YoY Change | 14.88% | 4.93% | 72.59% |
| Operating Profit | -$2.090M | -$2.214M | -$2.712M |
| YoY Change | -22.92% | -23.43% | 134.94% |
| Interest Expense | $3.906K | $340.0K | $2.613K |
| YoY Change | 49.48% | -113.71% | -101.91% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $253.8K | -$2.454M | |
| YoY Change | -110.34% | -1470.0% | |
| Pretax Income | -$1.836M | -$2.330M | -$4.717M |
| YoY Change | -61.07% | -56.69% | 383.75% |
| Income Tax | $0.00 | -$320.0K | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$1.836M | -$2.000M | -$4.717M |
| YoY Change | -61.07% | -59.92% | 383.75% |
| Net Earnings / Revenue | -101.44% | -113.57% | -652.35% |
| Basic Earnings Per Share | -$0.08 | -$0.19 | |
| Diluted Earnings Per Share | -$75.41K | -$0.08 | -$0.19 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 25.41M shares | 25.37M shares | 24.64M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q1 | 2015 Q4 | 2015 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $6.000M | $7.500M | $13.40M |
| YoY Change | -55.22% | 36.36% | 19.64% |
| Cash & Equivalents | $3.537M | $5.317M | $10.42M |
| Short-Term Investments | $2.500M | $2.200M | $2.900M |
| Other Short-Term Assets | $200.0K | $500.0K | $100.0K |
| YoY Change | 100.0% | -28.57% | -50.0% |
| Inventory | $1.100M | $1.191M | $702.9K |
| Prepaid Expenses | |||
| Receivables | $800.0K | $648.9K | $700.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $8.000M | $9.860M | $14.88M |
| YoY Change | -46.24% | 29.62% | 25.82% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $600.0K | $557.3K | $330.3K |
| YoY Change | 81.65% | 126.71% | 112.55% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $900.0K | $836.7K | $652.2K |
| YoY Change | 37.99% | 35.88% | 59.2% |
| Total Long-Term Assets | $1.500M | $1.394M | $982.5K |
| YoY Change | 52.66% | 61.79% | 73.87% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $8.000M | $9.860M | $14.88M |
| Total Long-Term Assets | $1.500M | $1.394M | $982.5K |
| Total Assets | $9.500M | $11.25M | $15.86M |
| YoY Change | -40.12% | 32.89% | 28.01% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $900.0K | $684.6K | $475.2K |
| YoY Change | 89.39% | -1.96% | -9.94% |
| Accrued Expenses | $800.0K | $700.0K | $700.0K |
| YoY Change | 14.29% | -12.5% | 75.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | ||
| YoY Change | |||
| Total Short-Term Liabilities | $3.248M | $3.044M | $6.198M |
| YoY Change | -47.59% | -32.44% | 87.91% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $3.248M | $3.044M | $6.198M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $3.200M | $3.044M | $6.200M |
| YoY Change | -48.39% | -32.36% | 87.88% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$134.4M | -$132.5M | -$129.1M |
| YoY Change | 4.07% | 6.54% | |
| Common Stock | $25.41K | $25.40K | $24.68K |
| YoY Change | 2.95% | 8.98% | -91.75% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $6.264M | $9.847M | $9.666M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $9.512M | $11.25M | $15.86M |
| YoY Change | -40.04% | 32.89% | 28.01% |
Cashflow Statement
| Concept | 2016 Q1 | 2015 Q4 | 2015 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.836M | -$2.000M | -$4.717M |
| YoY Change | -61.07% | -59.92% | 383.75% |
| Depreciation, Depletion And Amortization | $30.00K | $30.00K | $20.00K |
| YoY Change | 50.0% | 0.0% | |
| Cash From Operating Activities | -$1.260M | -$2.230M | -$2.409M |
| YoY Change | -47.7% | 6.7% | 201.08% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $35.81K | -$220.0K | $104.0K |
| YoY Change | -65.57% | 15.79% | 386.69% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$300.0K | -$250.0K | -$990.0K |
| YoY Change | -69.7% | -104.62% | -79.16% |
| Cash From Investing Activities | -$400.0K | -$470.0K | -$1.135M |
| YoY Change | -64.75% | -109.0% | -76.22% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $9.409M | ||
| YoY Change | -0.44% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 30.00K | 600.0K | $10.01M |
| YoY Change | -99.7% | 233.33% | 2.13% |
| NET CHANGE | |||
| Cash From Operating Activities | -1.260M | -2.230M | -$2.409M |
| Cash From Investing Activities | -400.0K | -470.0K | -$1.135M |
| Cash From Financing Activities | 30.00K | 600.0K | $10.01M |
| Net Change In Cash | -1.630M | -2.100M | $6.468M |
| YoY Change | -125.2% | -163.44% | 52.83% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.260M | -$2.230M | -$2.409M |
| Capital Expenditures | $35.81K | -$220.0K | $104.0K |
| Free Cash Flow | -$1.296M | -$2.010M | -$2.513M |
| YoY Change | -48.44% | 5.79% | 205.91% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
700462 | USD |
| CY2015Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
1394038 | USD |
| CY2015Q4 | us-gaap |
Assets
Assets
|
11254366 | USD |
| CY2014Q4 | us-gaap |
Assets
Assets
|
8468625 | USD |
| CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
684633 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
698307 | USD |
| CY2015Q4 | ctso |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
723018 | USD |
| CY2014Q4 | ctso |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
824884 | USD |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5316851 | USD |
| CY2014Q4 | us-gaap |
Inventory Net
InventoryNet
|
537566 | USD |
| CY2015Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
511927 | USD |
| CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
9860328 | USD |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
7607006 | USD |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
557289 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
245821 | USD |
| CY2015Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
836749 | USD |
| CY2014Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
615798 | USD |
| CY2015Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
2192000 | USD |
| CY2015Q4 | us-gaap |
Inventory Net
InventoryNet
|
1190681 | USD |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3605280 | USD |
| CY2015 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
4043819 | USD |
| CY2014 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
3135387 | USD |
| CY2015 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
735863 | USD |
| CY2014 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
978271 | USD |
| CY2015 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
2212546 | USD |
| CY2014 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
2133888 | USD |
| CY2014Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
1944547 | USD |
| CY2015Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
648869 | USD |
| CY2014Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
819151 | USD |
| CY2014Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
861619 | USD |
| CY2015Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
0 | USD |
| CY2014Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
833 | USD |
| CY2015Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
1636128 | USD |
| CY2014Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
2981418 | USD |
| CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3043779 | USD |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4505442 | USD |
| CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
25397 | USD |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
23305 | USD |
| CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
140126731 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
128106297 | USD |
| CY2015Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
584317 | USD |
| CY2014Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
227701 | USD |
| CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-132525858 | USD |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-124394120 | USD |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8210587 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3963183 | USD |
| CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
11254366 | USD |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
8468625 | USD |
| CY2015 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
11934 | USD |
| CY2014 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
9167 | USD |
| CY2014 | us-gaap |
Professional Fees
ProfessionalFees
|
896847 | USD |
| CY2015 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
6922515 | USD |
| CY2015 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
9301 | USD |
| CY2014 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-310024 | USD |
| CY2015 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-507276 | USD |
| CY2014 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-385956 | USD |
| CY2015 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-1345290 | USD |
| CY2014 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
2118498 | USD |
| CY2015 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
847315 | USD |
| CY2014 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2814478 | USD |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-8456344 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-9707314 | USD |
| CY2015 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-324606 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-385642 | USD |
| CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8131738 | USD |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9321672 | USD |
| CY2015 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
0 | USD |
| CY2014 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
9266673 | USD |
| CY2015 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-8131738 | USD |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-18588345 | USD |
| CY2015 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
356616 | USD |
| CY2015 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.33 | |
| CY2014 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.29 | |
| CY2014 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9037984 | USD |
| CY2015 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
0 | USD |
| CY2014 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
180100 | USD |
| CY2015 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
112969 | USD |
| CY2014 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
65547 | USD |
| CY2015 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
0 | USD |
| CY2014 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
198644 | USD |
| CY2015 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
0 | USD |
| CY2015 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
4791616 | USD |
| CY2014 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
4122825 | USD |
| CY2015 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3871069 | USD |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2431759 | USD |
| CY2015 | us-gaap |
Professional Fees
ProfessionalFees
|
1089145 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
283688 | USD |
| CY2015 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-7775122 | USD |
| CY2015 | us-gaap |
Gross Profit
GrossProfit
|
2579070 | USD |
| CY2014 | us-gaap |
Gross Profit
GrossProfit
|
1988937 | USD |
| CY2014 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
5553167 | USD |
| CY2015 | us-gaap |
Operating Expenses
OperatingExpenses
|
11882729 | USD |
| CY2014 | us-gaap |
Operating Expenses
OperatingExpenses
|
8881773 | USD |
| CY2015 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9303659 | USD |
| CY2014 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6892836 | USD |
| CY2014Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1024655 | USD |
| CY2014Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1162347 | USD |
| CY2014Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
873660 | USD |
| CY2014Q2 | us-gaap |
Gross Profit
GrossProfit
|
358504 | USD |
| CY2014Q3 | us-gaap |
Gross Profit
GrossProfit
|
686457 | USD |
| CY2014Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1363389 | USD |
| CY2014Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1483553 | USD |
| CY2014Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2891700 | USD |
| CY2014Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3227847 | USD |
| CY2014Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10491491 | USD |
| CY2015Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
10312500 | USD |
| CY2014 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
9751456 | USD |
| CY2015 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1711571 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1422250 | USD |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2183030 | USD |
| CY2015 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2014 | us-gaap |
Stock Issued1
StockIssued1
|
7137 | USD |
| CY2014 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
4106 | USD |
| CY2015 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-386435 | USD |
| CY2014 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
0 | USD |
| CY2015 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
382284 | USD |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
695841 | USD |
| CY2015 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-131970 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
412118 | USD |
| CY2015 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
632535 | USD |
| CY2014 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
303129 | USD |
| CY2015 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-178107 | USD |
| CY2014 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
108153 | USD |
| CY2015 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
7134 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
4784 | USD |
| CY2015 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-83169 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
497453 | USD |
| CY2015 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-833 | USD |
| CY2014 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-271526 | USD |
| CY2015 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
403608 | USD |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
153157 | USD |
| CY2015 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
239839 | USD |
| CY2014 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
214165 | USD |
| CY2015 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
5430547 | USD |
| CY2014 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
4745000 | USD |
| CY2015 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
5678000 | USD |
| CY2014 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
6689547 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-890900 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-2311869 | USD |
| CY2015 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
410726 | USD |
| CY2014 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
109200 | USD |
| CY2015 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1705433 | USD |
| CY2014 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
156250 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
11640242 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
10016906 | USD |
| CY2015 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-28837 | USD |
| CY2014 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
378406 | USD |
| CY2015 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
9524083 | USD |
| CY2015 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
0 | USD |
| CY2014 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
1990440 | USD |
| CY2015 | ctso |
Supplemental Noncash Transactions
SupplementalNoncashTransactions
|
1019207 | USD |
| CY2014 | ctso |
Supplemental Noncash Transactions
SupplementalNoncashTransactions
|
748545 | USD |
| CY2015 | ctso |
Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
|
0 | USD |
| CY2014 | ctso |
Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
|
9266673 | USD |
| CY2015 | ctso |
Fair Value Warrant Liability
FairValueWarrantLiability
|
0 | USD |
| CY2014 | ctso |
Fair Value Warrant Liability
FairValueWarrantLiability
|
862920 | USD |
| CY2015Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
3275 | USD |
| CY2014Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
3756 | USD |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
25397056 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
25397056 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23304640 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23304640 | shares |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-14265547 | USD |
| CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
382284 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
695841 | USD |
| CY2014 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
0 | USD |
| CY2014 | ctso |
Dividends Preferred Stock Series B
DividendsPreferredStockSeriesB
|
-9028360 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
180100 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
24274708 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
300000 | USD |
| CY2014 | ctso |
Stock Issued During Period Value Offering
StockIssuedDuringPeriodValueOffering
|
10200000 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
748545 | USD |
| CY2014 | ctso |
Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
|
1990440 | USD |
| CY2015 | ctso |
Stock Issued During Period Value Stock Cash Warrants Exercised
StockIssuedDuringPeriodValueStockCashWarrantsExercised
|
1705433 | USD |
| CY2014 | ctso |
Stock Issued During Period Value Stock Cash Warrants Exercised
StockIssuedDuringPeriodValueStockCashWarrantsExercised
|
156250 | USD |
| CY2014 | ctso |
Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
|
0 | USD |
| CY2015 | ctso |
Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
|
0 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
0 | USD |
| CY2015 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
0 | USD |
| CY2014 | ctso |
Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
|
109200 | USD |
| CY2015 | ctso |
Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
|
410726 | USD |
| CY2015Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
723074 | USD |
| CY2015Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
963939 | USD |
| CY2015Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1343625 | USD |
| CY2015Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1760978 | USD |
| CY2015Q1 | us-gaap |
Gross Profit
GrossProfit
|
418593 | USD |
| CY2015Q2 | us-gaap |
Gross Profit
GrossProfit
|
498508 | USD |
| CY2015Q3 | us-gaap |
Gross Profit
GrossProfit
|
704795 | USD |
| CY2015Q4 | us-gaap |
Gross Profit
GrossProfit
|
957174 | USD |
| CY2014 | ctso |
Fair Value Warranty Liability Upon Issuance
FairValueWarrantyLiabilityUponIssuance
|
-862920 | USD |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2711629 | USD |
| CY2015Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2227459 | USD |
| CY2015Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2150296 | USD |
| CY2015Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2214275 | USD |
| CY2015Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4716942 | USD |
| CY2015Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
1434318 | USD |
| CY2015Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2847441 | USD |
| CY2015Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2001674 | USD |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.19 | |
| CY2015Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.06 | |
| CY2015Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.11 | |
| CY2015Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.08 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.19 | |
| CY2015Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.05 | |
| CY2015Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.11 | |
| CY2015Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.08 | |
| CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.20 | |
| CY2014Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.22 | |
| CY2014Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.84 | |
| CY2014Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1062172 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
1 | pure |
| CY2015 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
26400 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
10500 | USD |
| CY2014Q1 | us-gaap |
Gross Profit
GrossProfit
|
399635 | USD |
| CY2014Q4 | us-gaap |
Gross Profit
GrossProfit
|
544342 | USD |
| CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1154194 | USD |
| CY2014Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2089599 | USD |
| CY2014Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2779408 | USD |
| CY2015 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
9524083 | USD |
| CY2015 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.2 | pure |
| CY2015 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.05 | pure |
| CY2015 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>1. BASIS OF PRESENTATION:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents Medical Inc., its wholly-owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the “European Subsidiary”), collectively referred to as “the Company.”</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Based on its projections, the Company believes it may have to raise additional capital to fund its planned operations over the next twelve month period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2015, the Company had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">132,525,858</font>, which included net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,131,738</font> for the year ended December 31, 2015 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,321,672</font> for the year ended December 31, 2014. The Company’s losses have resulted principally from costs incurred in the research and development of its polymer technology and selling, general and administrative expenses. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. CytoSorbents’ ability to achieve profitability will depend, among other things, on successfully completing the development of its technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE Mark and for potential label extensions of the Company’s current CE Mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance our activities. No assurance can be given that the Company will be able to raise funds required to sustain its working capital needs or that funds will be available at favorable terms. In addition, no assurance can be given that the Company’s product development efforts will be successful, that the expiration of certain patents may adversely affect the company, that its current CE Mark will enable it to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of the Company’s products will be manufactured at a competitive cost and will be of acceptable quality, or that the Company will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1916951 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.00 | |
| CY2015 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
|
P8Y2M12D | |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
|
P8Y8M12D | |
| CY2015 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
|
P9Y | |
| CY2015 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends, valuation methods used to determine the fair value of the warrant liability and valuation methods used in determining any debt discount associated with the convertible securities.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
5.02 | |
| CY2015 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Concentration of Credit Risk</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2015, three distributors accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">48</font> percent of outstanding grant and accounts receivable. As of December 31, 2014, a U.S. Government agency accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">66</font> percent of outstanding accounts receivable. For the year ended December 31, 2015, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14</font> percent of revenue was from one U.S. government grant agency. For the year ended December 31, 2014, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24</font> percent of revenue was from two U.S. government grant agencies and approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12</font> percent of revenues was from one distributor.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
3.26 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
681000 | shares |
| CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
7.88 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
5.19 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
2502 | shares |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
0 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
45.80 | |
| CY2015 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
|
P3Y2M12D | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.97 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.74 | |
| CY2014 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
117252 | shares |
| CY2015 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
339621 | shares |
| CY2015Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
2.72 | |
| CY2015 | us-gaap |
Freight Costs
FreightCosts
|
145000 | USD |
| CY2014 | us-gaap |
Freight Costs
FreightCosts
|
103000 | USD |
| CY2015 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Reclassifications</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain reclassifications have been made to the December 31, 2014 financial statements in order to conform to the 2015 financial statement presentation. There was no change in the reported amount of the accumulated deficit as a result of these reclassifications.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
732800 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
227810 | shares |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
166287 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2302187 | shares |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2477279 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.37 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.56 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y2M12D | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y1M6D | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y1M6D | |
| CY2015Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
382099 | USD |
| CY2014Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
142693 | USD |
| CY2015Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
758562 | USD |
| CY2014Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
326047 | USD |
| CY2015Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
50020 | USD |
| CY2014Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
68826 | USD |
| CY2015 | us-gaap |
Advertising Expense
AdvertisingExpense
|
282000 | USD |
| CY2014 | us-gaap |
Advertising Expense
AdvertisingExpense
|
142000 | USD |
| CY2014Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
874530 | shares |
| CY2014Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
1.37 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
3.33 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
178446 | shares |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
|
0.18 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
0.21 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
582576 | shares |
| CY2015Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
794708 | shares |
| CY2015Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1114833 | shares |
| CY2015 | us-gaap |
Depreciation
Depreciation
|
87397 | USD |
| CY2014 | us-gaap |
Depreciation
Depreciation
|
48429 | USD |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3098263 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2702457 | USD |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2540974 | USD |
| CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2456636 | USD |
| CY2015 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
25573 | USD |
| CY2014 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
17118 | USD |
| CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
25500 | USD |
| CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
18500 | USD |
| CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
10500 | USD |
| CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
10500 | USD |
| CY2015Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
9600 | USD |
| CY2015Q4 | us-gaap |
Other Intangible Assets Net
OtherIntangibleAssetsNet
|
771795 | USD |
| CY2014Q4 | us-gaap |
Other Intangible Assets Net
OtherIntangibleAssetsNet
|
557528 | USD |
| CY2015Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
64954 | USD |
| CY2014Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
58270 | USD |
| CY2014Q4 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
92712.27 | shares |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
816000 | shares |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9451000 | USD |
| CY2014Q1 | ctso |
Subscription Agreement Offering Units
SubscriptionAgreementOfferingUnits
|
1632000 | shares |
| CY2014Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
10200000 | USD |
| CY2014Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
293758 | USD |
| CY2015Q4 | ctso |
Accrued Travel And Entertainment Expence Current
AccruedTravelAndEntertainmentExpenceCurrent
|
219627 | USD |
| CY2014Q4 | ctso |
Accrued Travel And Entertainment Expence Current
AccruedTravelAndEntertainmentExpenceCurrent
|
107542 | USD |
| CY2015Q4 | ctso |
Clinical Study Costs Payable Current
ClinicalStudyCostsPayableCurrent
|
0 | USD |
| CY2014Q4 | ctso |
Clinical Study Costs Payable Current
ClinicalStudyCostsPayableCurrent
|
36465 | USD |
| CY2015Q4 | ctso |
Sales Payroll And Income Taxes Payable Current
SalesPayrollAndIncomeTaxesPayableCurrent
|
22592 | USD |
| CY2014Q4 | ctso |
Sales Payroll And Income Taxes Payable Current
SalesPayrollAndIncomeTaxesPayableCurrent
|
64745 | USD |
| CY2015Q4 | ctso |
Accrued Salaries And Commissions Current
AccruedSalariesAndCommissionsCurrent
|
141606 | USD |
| CY2014Q4 | ctso |
Accrued Salaries And Commissions Current
AccruedSalariesAndCommissionsCurrent
|
204515 | USD |
| CY2015Q3 | ctso |
Aggregate Registered Amount For Offerings
AggregateRegisteredAmountForOfferings
|
100000000 | USD |
| CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
150121 | USD |
| CY2015Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
102586 | USD |
| CY2014Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
45200 | USD |
| CY2015Q4 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
30000 | USD |
| CY2014Q4 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
30000 | USD |
| CY2015Q4 | ctso |
Accrued Director Fees Current
AccruedDirectorFeesCurrent
|
19250 | USD |
| CY2014Q4 | ctso |
Accrued Director Fees Current
AccruedDirectorFeesCurrent
|
11250 | USD |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
37236 | USD |
| CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
31409 | USD |
| CY2015Q4 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
28880 | shares |
| CY2015Q4 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
225000 | USD |
| CY2013Q2 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
1098000 | USD |
| CY2013Q2 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.08 | pure |
| CY2013Q2 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
3.125 | |
| CY2013Q2 | ctso |
Debt Instrument Percent Of Principal Amount
DebtInstrumentPercentOfPrincipalAmount
|
0.5 | pure |
| CY2013Q2 | ctso |
Warrant Exercise Price
WarrantExercisePrice
|
3.75 | |
| CY2014Q2 | us-gaap |
Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
|
379469 | shares |
| CY2013Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
745000 | USD |
| CY2013Q3 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.08 | pure |
| CY2013Q3 | ctso |
Debt Instrument Percent Of Principal Amount
DebtInstrumentPercentOfPrincipalAmount
|
0.5 | pure |
| CY2013 | us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
1843000 | USD |
| CY2013Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
1511883 | USD |
| CY2013Q4 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
171012 | USD |
| CY2013 | us-gaap |
Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
|
160105 | USD |
| CY2015 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
0 | USD |
| CY2014 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
199000 | USD |
| CY2013Q2 | ctso |
Debt Instrument Maturity Period
DebtInstrumentMaturityPeriod
|
P1Y | |
| CY2013Q3 | ctso |
Debt Instrument Maturity Period
DebtInstrumentMaturityPeriod
|
P1Y | |
| CY2015Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
1250000 | shares |
| CY2015Q1 | us-gaap |
Share Price
SharePrice
|
8.25 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9409000 | USD |
| CY2014Q1 | us-gaap |
Share Price
SharePrice
|
6.25 | |
| CY2014Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
7.8125 | |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
0.50 | shares |
| CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
7.8125 | |
| CY2014Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
816000 | shares |
| CY2014Q1 | ctso |
Fair Value Warrant Liability
FairValueWarrantLiability
|
862920 | USD |
| CY2014Q1 | us-gaap |
Share Price
SharePrice
|
6.00 | |
| CY2014Q1 | ctso |
Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
|
2762500 | USD |
| CY2014Q1 | ctso |
Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
|
16575000 | USD |
| CY2014Q1 | ctso |
Cash Placement Agent Fee As Percentage Of Gross Proceeds Of Sale Of Units
CashPlacementAgentFeeAsPercentageOfGrossProceedsOfSaleOfUnits
|
0.06 | pure |
| CY2015Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
736000 | shares |
| CY2014Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
816000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
7.8125 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.665 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.283 | pure |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0135 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0143 | pure |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P3Y2M8D | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y2M8D | |
| CY2015Q4 | us-gaap |
Share Price
SharePrice
|
5.85 | |
| CY2014Q4 | us-gaap |
Share Price
SharePrice
|
10.22 | |
| CY2011Q4 | ctso |
Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
|
8500000 | USD |
| CY2015 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
411000 | USD |
| CY2014 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
328000 | USD |
| CY2006Q3 | ctso |
License Period
LicensePeriod
|
P18Y | |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
265879 | USD |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
119750 | USD |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
385629 | USD |
| CY2015Q1 | ctso |
Underwriters Expenses
UnderwritersExpenses
|
85000 | USD |
| CY2015 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
382000 | USD |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
696000 | USD |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0195 | pure |
| CY2015Q2 | ctso |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInPeriodFairValue
|
1388000 | USD |
| CY2015Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
393000 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
14746091 | USD |
| CY2015 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P8M26D | |
| CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
|
566000 | shares |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
48960 | shares |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
7.50 | |
| CY2015 | dei |
Document Type
DocumentType
|
10-K | |
| CY2015 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2015 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2015-12-31 | |
| CY2015 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | |
| CY2015 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2015 | dei |
Entity Registrant Name
EntityRegistrantName
|
Cytosorbents Corp | |
| CY2015 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001175151 | |
| CY2015 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2015 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2015 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2015 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2015 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2015Q2 | dei |
Entity Public Float
EntityPublicFloat
|
104000000 | USD |
| CY2015 | dei |
Trading Symbol
TradingSymbol
|
CTSO | |
| CY2016Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
25406056 | shares |
| CY2015 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24885809 | shares |
| CY2014 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
14382813 | shares |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0086 | pure |
| CY2015Q4 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
8.02 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-9008934 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6661193 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
25 | pure |
| CY2015Q4 | ctso |
Number Of Patents Issued
NumberOfPatentsIssued
|
32 | pure |
| CY2015Q4 | ctso |
Number Of Countries In Which Product Marketed
NumberOfCountriesInWhichProductMarketed
|
32 | pure |
| CY2014Q1 | ctso |
Out Of Pocket Expenses As Percentage Of Gross Proceeds
OutOfPocketExpensesAsPercentageOfGrossProceeds
|
0.02 | pure |
| CY2015 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
-324606 | USD |
| CY2014 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
-385642 | USD |
| CY2015 | us-gaap |
Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
|
0 | USD |
| CY2014 | us-gaap |
Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
|
0 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
13041156 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
11073004 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1113151 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
-12065 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
0 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
14749297 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
11073004 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
11073004 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
3206 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
3206 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
0 | USD |
| CY2015Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
0 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
0 | USD |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.340 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.340 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.010 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.434 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.340 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.038 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
-0.036 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.031 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.015 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.051 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0 | pure |
| CY2015 | ctso |
Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
|
-0.029 | pure |
| CY2014 | ctso |
Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
|
0.010 | pure |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-8456344 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-9707314 | USD |
| CY2015 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
3673088 | USD |
| CY2014 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
2771746 | USD |
| CY2013Q3 | ctso |
Warrant Exercise Price
WarrantExercisePrice
|
3.125 | |
| CY2013Q3 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
2.50 |
